Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
October 28, 2020 at 10:00 am
Share
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 599.609 million compared to CNY 870.192 million a year ago. Operating loss was CNY 132.700 million compared to operating Income of CNY 13.380 million a year ago. Net loss was CNY 123.727 million compared to net income of CNY 43.602 million a year ago. Basic loss per share from continuing operations was CNY 0.594 compared to basic earnings per share from continuing operations of CNY 0.2093 a year ago.
ShanXi C&Y Pharmaceutical Group Co., Ltd. is principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Companyâs main products include anti-infective agents, respiratory system agents, cardiovascular drugs, antidepressant drugs, urinary system agents, pediatric agents and other drugs, as well as pharmaceutical raw materials and pharmaceutical intermediates. It also involves in the manufacture and distribution of health food products, as well as the provision of deoxyribonucleic acid (DNA) genetic preservation and pregnant environment testing services. The Company distributes its products in domestic market.
SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD. 
